Bioactive collagen peptides Fortigel from Gelita has been authorized by the National Health Agency (Anvisa) in Brazil to carry the claim “may contribute to the maintenance of joint health.”
The National Health Agency (Anvisa) in Brazil authorized the claim “may contribute to the maintenance of joint health” on the labels of food supplements containing the Bioactive Collagen Peptides Fortigel by Gelita (Eberbach, Germany).
“Fortigel is the first type I collagen to receive this joint approval,” said LéiaTomazPipulini, head of the nutrition & health ingredients business unit at GELITA South America, in a press release. “Supported by several studies carried out by the international scientific community, proving its effectiveness, and confirming the premise that not all collagens are the same. It is gratifying that the functional effectiveness of our solution dedicated to joint health received this important approval from the regulatory agency in the Brazilian market.”
“Independent clinical studies have shown that the daily intake of 5 grams of the Bioactive Collagen Peptides with an average molecular mass of 3kDa (Fortigel brand) helps in the reconstruction of the extracellular matrix of the joint cartilage,” according to Georgia Alvares de Castro MSc PhD, scientific consultant at Gelita. “Through an increased biosynthesis of type II collagen and proteoglycans Fortigel maintains normal joint function, contributes to the reduction of joint discomfort and thus improving mobility. Due to the physiological and metabolic action on cartilage tissue, it is possible to observe a reduction in the pain scale as a clinical outcome.”